These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 19430877)
1. Pharmacologic treatment to prevent fractures: from markers to patients. Cummings SR Osteoporos Int; 2009 May; 20 Suppl 3():S255-6. PubMed ID: 19430877 [No Abstract] [Full Text] [Related]
2. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate]. Shiraki M Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147 [No Abstract] [Full Text] [Related]
5. [When should bisphosphonate treatment be discontinued?]. Eriksen EF; Halse J Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131 [No Abstract] [Full Text] [Related]
6. Monitoring strontium ranelate therapy in patients with osteoporosis. Kendler DL; Adachi JD; Josse RG; Slosman DO Osteoporos Int; 2009 Jul; 20(7):1101-6. PubMed ID: 19266136 [TBL] [Abstract][Full Text] [Related]
7. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Bobba R; Adachi JD Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178 [TBL] [Abstract][Full Text] [Related]
8. Summary for Patients: Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults. Ann Intern Med; 2023 Feb; 176(2):I24. PubMed ID: 36592458 [No Abstract] [Full Text] [Related]
10. Are beta-blockers useful in the prevention of osteoporotic fractures? Pérez-Castrillón JL; De Luis DA; Duenas-Laita A Eur Rev Med Pharmacol Sci; 2009; 13(3):157-62. PubMed ID: 19673165 [TBL] [Abstract][Full Text] [Related]
11. [New bone density conservation agents for osteoporosis under research and development: ED-71]. Hagino H Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148 [No Abstract] [Full Text] [Related]
12. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Seeman E Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058 [TBL] [Abstract][Full Text] [Related]
14. From Bench to Bedside: An Ounce of (Opportunistic) Prevention. Potter BK Clin Orthop Relat Res; 2018 Apr; 476(4):687-688. PubMed ID: 29481367 [No Abstract] [Full Text] [Related]
15. [Osteoporosis treatment]. Uebelhart B; Rizzoli R Rev Med Suisse; 2006 Jan; 2(47):47-51. PubMed ID: 16465945 [TBL] [Abstract][Full Text] [Related]
16. One year in review 2018: progress in osteoporosis treatment. Figliomeni A; Signorini V; Mazzantini M Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765 [TBL] [Abstract][Full Text] [Related]
17. Study shows that a new type of osteoporosis drug reduces fracture risk. Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553 [No Abstract] [Full Text] [Related]
18. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Osteoporosis. Cotts KG; Cifu AS JAMA; 2018 Mar; 319(10):1040-1041. PubMed ID: 29536084 [No Abstract] [Full Text] [Related]
20. Osteoporosis, fractures, and risk of falls. Cohen MJ; Naeim A Oncology (Williston Park); 2010 Jul; 24(8):752-3. PubMed ID: 20718255 [No Abstract] [Full Text] [Related] [Next] [New Search]